Fast Charge: Why Ultra-Accurate Liquid Biopsies May Change Diagnosis, Treatment, And Trust In Women’s Health

Welcome And Mission

Speaker
0:00

Welcome

to

Endo Battery

Fast

Charged,

a

series

dedicated

to

keeping

you

informed

and

empowered

in

the

realm

of

endometriosis.

Teaming

up

with

board

certified

patient

advocates,

we

bring

you

the

latest

articles,

research,

and

insights

to

equip

you

with

accurate

information

and

a

deeper

understanding.

Whether

you're

expanding

your

knowledge,

staying

updated,

or

seeking

clarity,

you're

in

the

right

place.

I'm

your

host,
Alanna,

and

this

is

Endo battery

Fast

Charged,

charging

and

empowering

your

life

with

knowledge.

Guest Introduction And Credentials

Speaker
0:33

Welcome

back

to

Endo Battery

Fast

Charge,

where

we

power

through

the

latest

research

shaping

endometriosis

in

women's

health.

I

couldn't

be

more

excited

to

have

our

very

first

guest

on

this

series,

Dr.

Canio

Martinelli,

an

OBGYN

specialist

and

the

head

of

clinical

program

at

Savaro

Health

Research

Organization

at

Temple

University.

Dr.

Martinelli,

recently

named

FDAA

AACR

Oncology

Educational

Fellow,

is

at

the

forefront

of

translating

cutting-edge

science

into

real-world

impact.

His

work

connects

emerging

research,

clinical

care,

and

the

future

treatment

for

people

with

endometriosis,

helping

us

better

understand

where

innovation

can

truly

change

lives.

And

just

as

a

friendly

reminder,

correlation

does

not

equal

causation.

So

let's

keep

our

curiosity

fully

charged,

but

stay

grounded

as

we

dig

in.

Sponsor Message And Listener Support

Speaker
1:27

You

know

how

I

always

say

grab

a

cup

of

coffee

or

a

cup

of

tea

and

join

me

at

the

table

before

we

get

started?

Well,

what

if

that

cup

could

do

more

than

just

taste

good?

Meet

Strong

Coffee

Company,

my

little

secret

weapon.

It's

premium

instant

coffee

loaded

with

protein

MCTs

and

adaptogens

so

you

get

smooth

energy,

sharp

focus,

and

none

of

that

jittery

crash.

Basically,

it's

coffee

that

actually

shows

up

for

you.

Use

my

promo

code

Endo battery

for

an

exclusive

20%

discount.

And

yes,

when

you

do,

you're

helping

me

keep

these

expert

conversations

brewing

here

at

Endo Battery.

So

go

on,

grab

your

cup,

power

up

by

going

to

strongcoffeecompany.com

and

using

the

code

EndoBattery.

And

let's

make

this

episode

even

better.

What Is A Liquid Biopsy

Speaker
2:16

Let's

get

into

this.

Thank

you

so

much,

Canio,

for

joining

me

and

sitting

down

and

going

over

this

research.

With

all

the

advances

coming

up,

what

is

one

of

the

things

that

you've

been

researching

that

is

exciting

for

people

across

all

aspects

of

women's

healthcare?

Speaker 1
2:32

Thank

you

so

much

for

your

incredible

question.

Because

uh

we're

always

looking

for

something

that

can

be

really

game-changing.

And

one

of

the

things

that

has

been

game-changing

is

liquid

biopsy.

It's

a

kind

of

uh

strange

concept

because

whenever

we

think

about

biopsy,

it's

something

that

you

do

in

medicine

when

uh

you

took

a

solid

part

of

the

body

out

of

the

body

of

the

patient,

and

then

you

examine

on

a

pathological

uh

examination

and

you

get

the

report.

Here

the

liquid

biopsy

is

a

conceptually

a

completely

another

stuff

because

uh

you

can

get

some

sample

of

any

liquid

of

the

body.

Basically,

the

the

project

started

with

blood,

but

it

can

be

saliva,

urine,

it

can

be

tears.

And

the

idea

is

uh

being

able

to

find

in

that

sample

something

that

we

can

use

to

better

understand

the

disease,

but

also

to

improve

our

management

in

uh

in

healthcare.

And

that's

the

beauty

of

things,

because,

for

example,

how

is

it

possible

that

if

you

have

an

ovarian

cancer

or

endometrial

endometriosis,

you

know,

those

are

diseases

that

start

in

the

ovary,

in

the

peritoneum,

or

uh

like

uh

all

over

the

body,

even

for

endometriosis.

But

uh

how

do

you

get

sample

of

that

disease

in

the

blood,

for

example,

on

or

in

the

menstruation

on

in

the

uterine

bleeding?

Uh

well,

the

beauty

of

this

is

that

first

of

all

you

need

to

understand

the

biology

of

the

disease.

Because

whenever

you

develop

a

tool

in

medicine,

uh

it's

not

just

enough

developing

the

tool.

It

needs

to

be

then

uh

you

need

to

show

how

you

want

Finding Disease Fingerprints In Fluids

Speaker 1
4:15

to

implement

the

management

within

with

the

new

tool.

Because

if

you

introduce

something

new,

it

doesn't

mean

that's

necessary

much

better

than

what

you're

already

doing.

And

now

we

are

in

a

point

of

healthcare,

especially

in

oncology,

where

the

where

innovation

really

brought

us

in

in

a

fantastic

period

of

humanity

where

we

can

really,

there

are

still

very,

very

uh

fatal

diseases,

especially

when

you

get

ovarian

cancer

late

time.

But

uh

most

of

the

time,

if

you

can

get

them,

you

can

still

give

hope

to

people

and

give

nice

uh

chances.

So

whatever

you

are

doing

now

has

to

be

specific

for

specific

patients

that

needs

to

for

sure

give

much

uh

more

benefit

than

before.

So

you

cannot

just

try.

Uh

in

the

liquid

biopsy,

it's

it's

extremely

innovative

stuff

because

uh

you

can

be

less

invasive

because

you

can

take,

you

know,

uterine

bleeding

or

blood

sample,

and

you

can

do

extremely

fine

diagnosis.

It's

like

when

you

have

right

now,

if

you

have

a

cholesterol,

you

just

need

to

take

a

blood

sample,

right?

And

cholesterol

is

something

that

navigates

and

swim

in

the

blood.

Same

stuff

we

need

to

find

for

endometriosis

of

variant

cancer,

endometrial

cancer,

generally

with

the

cancer

works

much

better.

Something

that

circulates

in

these

uh

in

these

samples

and

being

able

to

detect

them

and

use

that

kind

of

detection

to

understand

the

disease

and

even

to

develop

something

new.

So,

if

I

want

to

have

a

kind

of

metaphor,

I

would

say

that

it's

like

for

the

FBI,

you

know,

using

fingerprints

to

find

criminals.

The

liquid

biopsy

is

exactly

the

same

thing.

We

will

use

fingerprints

that

cancer

endometriosis

live

in

the

in

the

in

the

blood

in

order

to

detect

them

as

early

as

we

can,

right

in

the

less

invasive

way

possible.

But

if

you

think

about

FBI

200

years

ago,

it

it

didn't

exist,

of

course,

but

let's

say

that

it

exists.

If

you

wanted

to

catch

a

criminal

by

using

fingerprints,

it

would

have

been

impossible

because

you

didn't

even

have

the

fingerprints.

Now

everybody

coming

to

US

didn't

need

to

give,

you

know,

to

record

fingerprints,

so

it's

very

easy.

What

we

are

doing

right

now

in

science

is

that

for

liquid

biopsy,

right

now

detecting

the

fingerprints

of

uh

uh

circulating

fingerprints

of

cancers

or

very,

very

high

inflammatory

diseases

such

as

endometriosis.

Yeah.

And

now

we

are

developing

that

you

can

look

at

different

reviews

and

editorial

that

we

we

wrote.

One

is

exactly

liquid

biopsy

in

gynaecological

cancer.

New Sensors And Accessibility

Speaker 1
6:47

The

other

one

is

called

uh

cancer

in

a

drop.

And

now

we

are

developing

together

with

uh

a

fantastic

team

from

Italy

new

sensors

in

order

to

detect

this

kind

of

uh

fingerprints,

this

is

uh

from

different

uh

samples

from

women

in

order

even

to

try

to

develop

uh

sensors

that

are

cheap

so

you

can

uh

let

everybody

use

uh

the

new

technology.

Accuracy, AI, And FDA Standards

Speaker
7:11

What

is

like

the

control

group

for

that

and

like

what's

the

accuracy

of

it

so

far?

Speaker 1
7:17

Exactly.

So

whenever

you

do

that,

you

have

a

population.

We

are

right

now

in

the

in

the

in

a

phase

where

we

are

training

the

system.

Speaker
7:26

Okay.

Speaker 1
7:27

There

are

already

some

commercial

available

um

like

uh

especially

for

endometriosis,

especially

in

US,

uh

tools

that

you

can

use

to

detect

endometriosis.

Some

of

them

with

even

uh

AI

powered,

they

say

that

they

can

have

an

accuracy

of

96%.

The

thing

is

that,

and

that's

another

actually

critical

paper

that

we

are

working

on.

There

are

different

kinds

of

papers,

you

know

better

than

me.

Is

that

FDA,

in

order

to

approve

AI

liquid

biopsy

test,

you

need

to

show

an

accuracy

that

is

higher

than

99%.

And

I

think

that

FDA

was

incredibly

smart

this

time

because

they

said,

okay,

you

wanna

do

that,

but

you

need

to

show

that

it's

incredibly

accurate.

Otherwise,

I'm

not

gonna

give

you

the

FDA

approval.

That's

why

lots

of

right

now

liquid

biopsy

tools

they

don't

have

they

don't

have

FDA

approval.

I

think

that's

very

important

because

what

is

I'm

gonna

ask

you

this

question

actually

to

you.

Like

let's

say

that

you're

a

young

girl

and

you

have

pain,

you

believe

you

are

of

endometriosis

and

you

live

in

a

place

in

the

US

all

over

the

world,

but

you

don't

have

an

easy

access

to

uh

like

real

specialist,

you

know,

of

endometriosis.

And

you

feel

pain,

you

feel

pain,

you

go

to

a

doctor

and

he

says,

uh,

you

don't

have

anything,

don't

worry,

you

are

a

woman.

Uh

and

then

you

take

the

test,

and

the

test

is

gonna

give

you

what

we

call

uh

false

negative.

So

the

test

is

gonna,

because

the

accuracy

is

not

very,

very

high,

the

test

is

gonna

tell

you

there

is

a

risk

that

tells

the

test

tells

you

you

you

don't

have

the

disease.

At

that

point,

you're

gonna

uh

basically

say

to

that

woman

that

your

life,

her

life

is

gonna

be

destroyed

for

the

rest

of

the

life

because

uh

she

will

have

the

confirmation

that

she

does

not

have

any

problem

and

she

will

convince

herself

that

she

needs

to

feel

that

pain.

So

again,

whenever

there

is

this

new

sexy

stuff

in

science,

validation

is

first

step.

Second

step

is

how

can

I

introduce

that

without

uh

creating

critical

problem

for

people?

Because

you

know,

when

you

when

you

see

the

test

and

the

test

test

is

negative,

you

don't

think

about

okay,

what's

the

accuracy

rate?

That's

a

question

that

you

uh

are

uh

like

right

now,

you're

making.

But

lots

of

people

they

don't

think

about

that

because

when

they

are

in

a

fight

or

flight

mode,

The Risk Of False Negatives

Speaker 1
9:50

they

just

are

focused

on

something,

they

don't

have

the

calm

to

to

really

be

rational

things.

So

we

need

to

be

very,

very

careful,

especially

when

people

want

to

make

money

out

of

this.

So

we

need

to

stand

up

for

people

who

says,

okay,

FDA

did

an

incredible

job

here,

I

have

to

say

that.

Speaker
10:07

Right.

So

this

study

is

essentially

is

it

going

to

be

an

analyzing,

like

creating

a

tool

that

analyzes

like

the

DNA

for

inflammatory

markers

and

genetic

mutations,

or

is

it

is

it

a

doing

it

through

different

sequencing?

Speaker 1
10:22

Well,

let's

say

that

we

are

working

on

different

kinds

of

sensor.

One

of

the

most

two

of

the

most

promising

one.

One

is

working

on

the

ventilation

of

the

DNA.

We

know

that

there

is

the

genomics

that's

actually

the

omic

related

to

the

sequence

of

the

DNA.

But

the

DNA

is

not

just

something

that

stays

there,

it's

uh

it's

a

living

stuff,

it's

something

they

change,

something

that

got

modified.

And

so

we

can

have

the

same

DNA,

but

there

could

be

different

modifications.

So

it's

called

epigenetics.

Right.

So

even

if

you

have

the

same

genomics,

it

doesn't

mean

that

you're

gonna

be

the

same.

Because

the

modification

of

the

DNA,

in

this

case,

uh

epigenetic

modification,

can

change

the

way

the

gene

expresses

themselves

into

proteins,

and

then

again

there

will

be

a

modification

of

the

proteins,

and

the

way

they

are

modified

will

determine

the

function

of

the

proteins.

And

if

you

put

all

of

these

layers

together,

you're

going

to

create

a

unique

pattern,

not

just

as

uh

like

uh

phenotypically

human,

but

even

from

a

functional

biological

distinction,

and

that's

the

thing.

So

being

able

to

see

the

methylation

pattern

of

all

the

DNA

can

give

nice

information,

especially

related

to

inflammation,

like

inflammatory

disease

such

as

endometriosis,

because

they're

gonna

leave

a

fit

like

we

said,

a

fingerprint

somehow.

Like

if

you

don't

wanna

commit

any

like

a

problem,

you

just

don't

create

problem.

If

you

do

something,

you

can

hide,

but

someone

is

gonna

find

you.

That's

we

are

in

that

phase.

We're

gonna

find

we

know

that

endometriosis

is

something

invasive,

it's

something

that

whenever

you

know

it

got

attached

to

somewhere

in

the

body,

it

has

to

do

something.

Maybe

the

signal

is

very,

very

low,

What The Tests Measure: Genomics To Epigenetics

Speaker 1
12:07

and

when

the

signal

is

low,

we

can

use

AI

stuff

to

like

enhance

the

signal,

but

we're

getting

to

that.

Speaker
12:13

Interesting.

I

think

what's

important

too,

and

what

you're

saying

is

like

the

FDA

did

a

good

job

in

this,

is

that

if

they're

giving

false

negatives,

that

also

plays

into

the

mental

aspect

of

things,

like

how

that

kind

of

disrupts

our

cognitive

function

in

a

way,

and

and

our

mental

health

and

everything

else.

Like

there's

there's

something

to

be

said

about

making

sure

something

is

very

accurate

and

giving

voice

to

what

we're

going

through.

And

that's

what

you're

saying

is

like

you're

getting

to

a

point

where

this

is

accurate

diagnosis

without

the

invasive

surgery.

Speaker 1
12:50

Absolutely.

And

uh,

it's

even

about

uh,

you

know,

it's

uh

it's

a

way

to

explain

people

how

really

healthcare

is,

because

uh

let's

say

that

you

don't

have

absolutely

any

access

to

healthcare,

you

are

in

a

rural

place

in

the

world,

and

that's

the

only

chance

you

have,

you

know,

maybe

you

can

use

it,

but

being

aware

that

if

it's

negative,

it's

not

necessarily

negative.

Speaker
13:11

Right.

Speaker 1
13:12

But

if

you

have

the

chance

to

get

access

to

uh

a

very

experienced

surgeon,

then

I

won't

spend

any

money

on

this

stuff.

I

will

just

get

to

the

experienced

surgeon.

And

uh

let

me

share

with

you

with

this.

Uh

my

mom

is

uh

right

now,

actually,

the

issue

is

gonna

turn

70

years

old.

She

is

a

doctor

and

she's

an

old

school

doctor.

She

always

tells

me

you

have

to

listen

to

patients.

If

there

is

a

problem,

if

they

say

that

there

is

a

problem,

the

problem

is

there.

Yes,

whatever

it

is,

you

know,

it

can

be

organic,

mental,

whatever

it

is,

but

there

is

a

problem.

If

you

want

to

convince

the

patient

that

she

does

not

have

a

problem,

that's

because

you're

not

able

to

find

out

what

the

problem

is.

Yeah,

that's

okay.

But

you

need

to

recognize,

to

assess

the

presence

of

the

problem.

You

cannot

solve

it.

You

send

to

another

uh

colleague,

you

remove

something,

you

do,

you

organize

something,

you

go

to

the

you

can

instantly

say,

you

know,

no,

as

a

doctor,

we

believe

we

need

to

be

uh

superhuman.

Absolutely

not.

Need

to

be

sincere

to

people.

So,

okay,

maybe

I

don't

know

that.

I'm

sorry.

I

understand

that

there

is

a

problem,

I

can

feel

it.

You

tell

me,

actually,

so

you

know,

you're

telling

me

right.

Uh

I

can

I

I'm

gonna

help

you,

I'm

gonna

do

the

best

I

can

in

my

knowledge

and

my

connection.

And

uh

at

the

end,

again,

everything

cool

in

tech

and

in

science

needs

to

be

damn

fit

in

the

in

the

in

the

right

way.

Speaker
14:35

Yeah.

Well,

it's

also

a

tool

of

validation.

I

think

that's

kind

of

a

big

thing

for

a

lot

of

people

because

I

mean

this

is

like

it's

a

tool

that

we

could

utilize

when

we

are

seeing

providers

who

don't

really

know

a

lot

about

endometriosis.

I

think

that's

such

a

cool

avenue

for

us

to

be

able

to

go

into

with

the

caveat

of

saying

we

don't

always

know

for

certain

100%

that

it's

not

there.

Right.

Speaker 1
15:00

That

means

that

whenever

you

want

to

use

a

tool,

then

uh

without

the

physician

in

the

loop,

people

need

to

be

aware

about

how

it

works.

I

know

that

self-education

is

you

know

hard

to

do.

If

we

don't

talk

about

medicine

or

something

else

like

finance,

engineering,

you

know,

I

can

try

to

self-educate

Mental Health, Access, And Clinical Judgment

Speaker 1
15:20

me,

but

then

you

need

to

trust

patient

advisor,

someone

else

that

that

already

went

through

that

and

then

uh

you

know

always

talk

to

people.

Speaker
15:29

Yeah.

What

advances

will

this

bring

for

research,

though?

I

think

that's

kind

of

an

important

step,

is

like

research

is

great,

but

how

will

it

advance

more

research?

What

are

what

do

you

think

the

goal

would

be

for

that?

Speaker 1
15:41

Regarding

liquid

biopsy

is

something

that

is

already

happening

in

uh

in

uh

in

the

oncology

field,

uh,

and

it's

something

that

is

already

here.

So

it's

happening

today.

If

I'm

able

to

detect

cancer

earlier,

um

I'm

not

just

able

to

use

different

treatments

or

change

the

management,

but

also

able

to

even

give

uh

the

green

light

for

some

drugs

that

are

being

uh

developing

right

now.

Because

uh,

whenever

you

introduce

new

drug,

you

need

to

validate

those

through

uh

years

and

years

of

studies,

like

five,

six

years,

and

they

have

to

follow

up.

And

then,

you

know,

during

the

validation

of

the

new

drug,

only

the

people

that

fit

within

the

trial

can

benefit

from

the

new

drug.

There

is

lots

of

people

that

won't

benefit

from

that

drug

unless,

you

know,

until

the

the

study

will

be

over.

In

this

way,

is

something

that

is

working

on

this.

If

we

find,

and

we

already

found

in

some

specific

case

a

target

in

the

liquid

biopsy

that

are

related

with

clinical

outcomes,

so

they

really

have

a

clinical

meaning,

it

means

that

I

can

accelerate,

I

can

speed

up

the

process

of

validation

of

drug.

So

it's

gonna

give

a

great

boost

even

uh

in

uh

in

drug

uh

validation

and

production.

Basically,

the

goal

is

even

uh

if

we

know

the

fingerprints,

every

cancer

can

give

a

different

fingerprint.

So

we

can

even

study

the

biology

behind

that

specific

cancer

and

being

able

even

to

do

what

we

call

molecular

guided

surgery.

So

whenever

you

open

a

patient,

you

just

not

remove

the

organ

or

the

tissue,

you

are

able

to

see

the

cancer

cells,

you're

able

to

visually

see

the

cancer

cells.

Okay,

I'm

gonna

remove

all

the

tiny

little

places.

Speaker
17:30

Interesting.

There's

so

much

hope

for

so

many

people.

It's

just

amazing

what

you're

able

to

do

with

tools

that

have

been

and

and

creativity,

you

know.

Are

there

studies

that

you

are

currently

working

on

that

are

gonna

push

the

boundaries

a

little

bit

in

patient-centered

care

or

diagnosis?

Speaker 1
17:51

And

you

can

talk

about

because

that's

always

so

there

is

a

molecular

medicine

project

ongoing

in

my

center,

uh,

especially

for

oncological

cancers.

I

may

not

say

the

name

of

the

target,

but

it's

something

that

has

to

do

with

cell

cycling

and

uh

translation

of

the

proteins.

The

idea

here

is

the

experimental

studies

right

now.

We

maybe

have

found

something

uh

that

if

we

target

can

slow

How Liquid Biopsy Accelerates Research And Drugs

Speaker 1
18:20

down

uh

the

oncogenesis

process

in

specific

cancers.

So

it's

just

a

new,

you

know,

a

new

target

that

may

be

useful

even

for

synthesizing

drug

resistance

because

uh

when

we

talk

about

AI,

when

we

talk

about

the

tools,

it's

something

that

uh

we

are

doing

in

order

to

enhance

the

ability

of

humans

to

cure

and

treat

patterns

to

see

new

data.

But

then

there

is

uh

the

other

part

of

the

science,

so

generate

new

data,

not

just

being

able

to

analyze

the

existing

one.

Uh

this

is

still

today,

there

are

something

that

we

are

advancing

with

the

eye,

but

still

kind

of

analogical.

So

it

means

that

whenever

we

found

a

pattern,

then

we

need

to

modify

the

cells

in

lab,

and

then

we

need

to

see

what's

happening

after

we

do

this

kind

of

genetic

editing,

and

then

we

need

to

skip

and

next

phases,

and

then

we

will

get

to

the

patient.

That's

the

part

of

the

research

that's

very,

very

exhausting

because

uh

whenever

you

modify

a

cell,

you

never

know

what's

happening.

Speaker
19:21

Right.

Speaker 1
19:22

One

gene

can

have

uh

a

role

in

one

cancer,

and

there's

a

complete

another

role

in

another

cancer,

and

then

there

is

another

one

gene,

as

we

said,

is

it's

not

just

one,

but

then

you

have

to

look

at

the

epigenetics

and

the

way

you

get

transcripted

in

RNA

and

the

gatting

gets

translated

in

proteins,

and

how

the

proteins

get

modified.

So

the

goal

here

is

uh

trying

to

put

all

as

again

all

the

layers

together,

otherwise

we

won't

understand

very

precisely

what's

going

on.

Speaker
19:50

Right.

Yeah.

There's

so

many

layers

to

all

of

this

research.

They're

insane.

And

I'm

excited

to

see

like

where

that

goes

because

you

know,

we

I

feel

like

a

lot

of

times

we

talk

about

needing

more

research,

but

we

there's

research

happening,

we

just

don't

know

it.

We

don't

know

what's

being

done.

And

yet

there's

people

that

are

starting

to

pay

more

and

more

attention

to

things

like

endometriosis

and

cancers

and

like

specifically

women's

health-related

research.

And

I

there's

people

that

are

passionate,

like

you,

who

are

putting

things

together.

We

just

aren't

always

aware

of

it.

And

it's

going

to

change

the

trajectory

of

those

living

with

this

disease

because

earlier

diagnosis,

better

care,

better

treatment,

better

precision

in

surgery,

what

uh

maybe

even

future

is

reversing

some

of

that

inflammatory

markers.

Speaker 1
20:43

Exactly.

Yes,

you're

getting

there.

See,

I

mean,

uh

that

that's

the

real

goal.

Like

we

publish

this

these

um

these

studies

called

endometriosis

cancer

mimicking,

is

on

it's

in

uh

the

annals

of

oncology

journal.

And

uh

the

cool

thing

about

that

is

uh

endometriosis.

I'm

sorry

if

I

say

cool,

but

it's

uh

scientifically

cool.

Let's

say

that

it's

not

a

is

that

endometriosis

looks

like

it

behaves

like

a

cancer,

but

it's

not

a

cancer,

but

has

some

traits

of

a

cancer.

And

as

you

said,

when

it

comes

to

cancer,

it's

a

very

paradoxical

stuff

because

uh

cancer

cells

discovered

how

to

become

immortal

because

uh

they

are

able

to

proliferate,

to

invade,

to

move,

to

metastasize,

Molecular-Guided Surgery And Hope

Speaker 1
21:29

so

they

are

super,

you

know,

supercells.

And

they

can

live

forever,

actually,

but

there

is

one

problem

they

will

die

once

they

will

kill

the

organism

they

are

into.

So

it's

kind

of

the

price

to

discover

immortality

is

actually

death.

And

it's

something

that

makes

me

reflect

a

lot

because

maybe

humans

not

made

for

immortality

because

the

price

to

pay

is

is

uh

is

death.

There

have

been

lots

of

uh

research

right

now

in

longevity,

aging,

trying

to

be

immortal

and

blah

blah

blah.

But

whenever

you

act

and

you

try

to

modify

some

natural

processing,

such

as

aging,

you

don't

know

what's

happening

there.

That's

why

most

of

the

anti-aging

stuff

in

the

long

term

or

hormone

treatment

long

term

have

been

associated

with

cancer

issues

and

cancer

risk

because

nature

is

a

very

specific

way

to

work

and

to

function.

And

whenever

you

want

to

change

it,

something

may

happen.

Speaker
22:27

Right,

right.

And

it

I

feel

like

endometriosis

is

definitely

always

leaving

us

on

this

path

of

like

which

way

is

it

gonna

go?

Like

it's

not

something

that

is

linear,

it

plays

by

its

own

rules.

Current Studies On Targets And Resistance

Speaker
22:41

Exactly.

Speaker 1
22:42

That's

something

that

science

learned

from

patient

because

uh

patient

understood

that

much

earlier

than

uh

physician

and

scientists.

Whenever

you

talk

with

the

patient

with

endometriosis,

you

know

that

her

story

is

completely

different

than

someone

else.

Someone

has

a

very

small

lesion

and

huge

pain,

someone

has

a

very

large

lesion

and

like

very,

very

soft

pain.

Someone

has

fertility

problems,

other

ones

has

intestinal

bowel

problems.

And

then

there

was

a

case

that

was

a

case

in

Italy

actually.

This

girl

has

endometriosis

in

the

brain.

And

so

it

happened,

you

know,

that

during

the

period

uh

uh

this

this

brain

lesion

started

to

bleed,

and

she

started

to

have

uh

epilepsy

uh

seizure,

and

then

after

the

period

everything

was

okay,

everybody

was

uh

ready

to

start

uh

for

you

know

they

thought

it

could

be

cancer.

They

started

to

do

the

they

wanted

to

do

the

excision

surgery

in

the

brain,

that's

very,

very

hard

and

debilitating.

But

somehow

there

was

a

discussion

where,

you

know,

it

was

uh

several

years

ago.

So

what

happened

is

uh

someone

noticed

the

correlation

with

the

periods

that

it

may

be

endometriosis.

And

so

they

put

uh

the

patient

under

hormonal

treatment

to

stop

the

let's

say

the

the

period,

the

cycle,

and

she

was

completely

fine.

So

it

was

endometriosis,

brain

endometriosis.

So

you

see

that

we

are

talking

about

endometriosis

as

a

single

disease,

but

already

has

been

years

that

patient

already

telling

us

that

endometriosis

is

not

a

single

disease,

so

it's

not

something

that

we

discover

like,

oh,

we're

genius.

No,

we're

just

opening

the

eyes.

We

just

right

now,

what

we

need

to

do

is

finding

the

resources,

the

team,

the

collaboration

to

keep

working

on

that.

And

that's

the

paper

we're

talking

about.

We

did

a

research

and

we

saw

that

endometriosis

is

like

having

a

car

for

each

patient.

You

know,

the

way

the

car

goes

and

depends,

the

way

you

use

uh

the

pedals,

the

way

you

drive,

uh

the

gears,

and

uh

so

you

can

shift

whatever

she

wants.

And

uh

the

question

is

there

is

the

way

to

detect

and

predict

the

behavior?

There

may

be,

because

in

the

study

what

we

propose

is

that

we

studied

all

the

possible

pathways

that

the

pneumatic

cells

are

can

be

possibly

activated,

doesn't

mean

that

the

pathways

are

active

at

the

The Many Layers From Gene To Protein

Speaker 1
25:03

same

time

altogether,

right?

So

now

the

goal

is

trying

to,

and

we

are

starting

a

collaboration

with

the

biotech,

I

cannot

say

the

name,

but

uh,

we're

starting

a

collaboration

to

see

through

specific

analysis

whether

these

uh

functionality

are

like

uh

specifically

related

to

specific

clinical

symptoms.

Interesting.

So

we

can

go

on

the

way

back,

so

from

the

clinical

symptoms,

we

can

then

uh

relate

with

the

biology

of

the

single

cells.

Speaker
25:31

Fascinating.

We're

changing

so

much

over

here

in

that

world.

Thank

you,

Kanye,

for

just

sitting

down

and

going

over

this

research.

I

hope,

I

hope

that

talking

to

you

and

people

being

in

this

conversation

and

hearing

this

gives

them

hope

that

there's

more

to

look

forward

to

in

endometriosis

research

and

care

and

in

women's

health

and

patient

outcomes,

not

just

looking

at

surgery,

but

looking

at

the

whole

picture.

You

are

doing

a

phen

phenomenal

job

of

thinking

outside

of

the

box

and

what

really

matters

not

only

to

the

patient

but

to

the

provider

and

looking

at

it

as

a

collective

effort

to

create

better

health

care

for

everyone.

And

so

thanks

for

breaking

this

research

down.

Thank

you

for

doing

it.

Thanks

for

you

know

being

passionate

about

this

because

this

is

what's

gonna

change

the

future.

Thank

you.

Speaker 1
26:28

I

wanna

let

me

let

me

thank

you

because

here

you're

doing

an

incredible

job

too.

If

we

will

be

successful,

it's

because

everybody

will

work

together

and

uh

we

will

commit

to

the

same

challenge.

And

uh,

the

history

of

the

world

is

showing

us

that

when

people

work

together,

we

can

do

that.

Alone,

of

course,

you

won't

go

farther.

Speaker
26:48

Right?

Speaker 1
26:48

No,

just

thank

you

so

much.

Speaker
26:50

Yes,

thank

you.

And

I

always

love

talking

to

you

and

I

love

spending

time

with

you,

so

it's

just

a

pleasure

all

around

to

be

able

to

do

this.

But

remember

everyone,

knowledge

is

power,

and

what

you

do

with

that

power

is

create

change.

So

until

next

time,

continue

advocating

for

you

and

for

others.